Member Info for LovableLumax

I’m not saying it makes a difference I’m suggesting it’s odd given your constant negativity uou would be holding. Pretty straightforward.

It sounds like Wyn isn’t holding (would be odd with his negative outlook) so he’s surely short? If he has no position then I really do feel sorry for him. Spending so much time on here without a financial interest is sad.

Cohorts 2,3 and 3 didn’t have an RNS saying dosing had taken place but an RNS saying the previous cohort had completed. They announced dosing on cohort 1 as trial commenced and cohort 5 and US due to the long break waiting for regulatory approval. C6 started likely end of June as they are presumably not lacking patients given the number of sites.

An increase in profits?! WTF?! You shouldn’t be investing.

Doxorubicin is a generic drug and the preCISION platform is patented so AVA6000 will be protected. The share price will do a lot better once P1a published or a licensing deal os signed. Given the general crap market Avacta not doing too badly.

can’t be ****d to look but it’s not difficult. number of shares in issue by price. also, p1a about safety and we have 6 biopsies showing the mechanism of action working for sure which meant efficacy pre-clinical and should do so in human as dox very well understood. price a snip.

Without a doubt and the IIs with shorts 0.5% or more have reduced or closed and Conifer has bought around 1.5m more shares comfortably above 100p.

With conversion coming up no doubt the shorting crew will work their socks off. Par for the course.

Likely RNS on Friday. That’ll be 20% of the loan repaid and we haven’t completed P1a so good going we’re above placing still. Have bounced off 100p for a good while so hopdully that’ll broadly remain the base.

I only mentioned as you put AIM market.

Anyway, agreed - Avacta Is Magic

FYI the AIM stands for the Alternative Investment Market.

I agree we need to move from AIM but not yet. Ideally we get funding in the next few months via licensing deals with decent up front payments. The share price will move up and stay there once more funding is secured IMO. P1a data should provide a fair few options.

Held/manipulated? Really. Look at the volume this month, no data above 1m traded which is around 0.3% of share capital.

it is shocking snd what’s more it was obvious they were on **** when gb didn’t do his usual proactive interview which he loved and did at fy and interim. when no video forthcoming alarm bells rang for some. it’d be interesting to know if he has selling without issuing rnss

Simone still dumping. Lows en route. Once the seller is done it’ll clearly bounce.

Okay fair enough.

Your research good but gave me the impression you still thought DVRG could survive. I hope you at least sold some and clawed some money back.

T-Rat FFS do you think shareholders wil get anything? Any monies recovered will go to debtors, redundancies institutions and then retail. GB either grossly incompetent or a fraudster. Interesting to know what his holding was before he left the business, it wouldn’t surprise me if he was selling on the way down without issuing RNSs.

Seller surely not finished.

Exactly. I was quoting the CEO.

Beinthelead that is not true. AS said they will release interim data once they have enough for it to be considered meaningful ie when there is statistical significance.

The global pharmaceutical sector has around $700 billion at its disposal to acquire other companies and invest in research and development, according to Goldman Sachs Research. That war chest will be important as patents expire for some of the industry's blockbuster drugs.

“The pharmaceutical industry will need growth, and at this time they are sitting on a tremendous amount of cash,” says Asad Haider, head of the healthcare business unit in Goldman Sachs Research. “The baseline expectation is that there is going to be continued M&A.”

I was also at the AGM and think dosing for cohort 6 has commenced (patient 1). AS said they only announced C5 dosing due to the large delay (whilst awaiting regulatory approval) and first US dosing. Aside from C1 the next dosings were not subject to an RNS just to say a cohort had completed.

FYI The fastest between cohorts was 29 June to 1 Sept which is 9 weeks and a day so 64 days.

AS also said in P1b once the trial reaches statistical significance they will be happy to publish interim data. I suspect at that point the vultures will be circling.